Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sibutramine and its cardiovascular profile


Sibutramine can produce dose-dependent increases in blood pressure and heart rate, especially during initial treatment. However, the cardiovascular effects of the drug are related to the weight loss achieved: patients who lose 5% or more of initial body weight have a reduction in blood pressure, which correlates with the degree of weight loss. Sibutramine does not exacerbate pre-existing controlled hypertension and treatment has been shown to be safe and effective in these patients. In clinical practice, it is important to observe the recommended exclusion criteria, to monitor blood pressure and heart rate and to adhere to the withdrawal criteria. This should enable the identification of those patients for whom sibutramine is not suitable while permitting the majority of patients to gain clinical benefit from treatment.

Author information



Corresponding author

Correspondence to K Narkiewicz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Narkiewicz, K. Sibutramine and its cardiovascular profile. Int J Obes 26, S38–S41 (2002).

Download citation


  • sibutramine
  • hypertension
  • blood pressure
  • heart rate
  • withdrawal criteria

Further reading


Quick links